Ibruxen140 mg

Ibruxen is a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of several B-cell lymphoid malignancies and chronic graft-versus-host disease (cGVHD).

Established / FDA-approved indications

• Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), including patients with 17p deletion — as first-line therapy or in relapsed/refractory disease, given alone or in combination with an anti-CD20 antibody such as rituximab or obinutuzumab.
• Waldenström's macroglobulinemia (WM) — as monotherapy or in combination with rituximab.
• Chronic graft-versus-host disease (cGVHD) in adult and pediatric patients (1 year of age and older) after failure of one or more prior lines of systemic therapy.

Historically approved / off-label use (evidence-limited)

• Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy — this indication received earlier accelerated approval but was later voluntarily withdrawn after confirmatory trials failed to show a survival benefit and raised safety concerns; Ibruxen may still be used off-label in select relapsed/refractory MCL cases at physician discretion when other options are limited.
• Marginal zone lymphoma (MZL) requiring prior anti-CD20-based therapy — similarly an earlier accelerated approval that was voluntarily withdrawn; use is now considered off-label.

The decision to use Ibruxen for any indication, and the specific regimen (monotherapy versus combination), should be individualized by a hematologist/oncologist based on disease characteristics, prior therapy, and patient fitness.

Each capsule of Ibrutinib available in Bangladesh contains 140 mg of Ibrutinib as the active ingredient. Internationally, Ibrutinib is also formulated as film-coated tablets (140 mg, 280 mg, 420 mg, 560 mg) and as an oral suspension, though capsules are the common local presentation.

Ibruxen is an orally administered, small-molecule inhibitor of Bruton's tyrosine kinase (BTK), a key signaling enzyme in the B-cell antigen receptor (BCR) and cytokine receptor pathways. By blocking BTK, Ibruxen interferes with the survival, proliferation, and migration signals that malignant B-cells depend on, leading to reduced tumor burden in B-cell lymphoid cancers. It also has activity in chronic graft-versus-host disease through inhibition of BTK in B-cells and interleukin-2-inducible T-cell kinase (ITK) in T-cells, which dampens the aberrant immune activation that drives cGVHD.

Ibruxen is taken once daily by mouth, with therapy typically continued long-term (until disease progression or unacceptable toxicity) under the supervision of a specialist experienced in treating hematologic malignancies.

Ibruxen belongs to the Bruton's tyrosine kinase (BTK) inhibitor class of targeted antineoplastic (small-molecule kinase inhibitor) agents.

Mechanism

Ibrutinib forms a covalent bond with a cysteine residue (Cys-481) in the active site of Bruton's tyrosine kinase (BTK), resulting in irreversible inhibition of BTK enzymatic activity. BTK is a component of the B-cell receptor (BCR) and cytokine receptor signaling pathways, and its inhibition blocks downstream survival and proliferation signals in malignant B-lymphocytes, promotes apoptosis, and reduces B-cell migration and adhesion within lymphoid tissue and bone marrow. In chronic GVHD, Ibrutinib additionally inhibits interleukin-2-inducible T-cell kinase (ITK), modulating pathogenic T-cell and B-cell activity.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral administration; peak plasma concentration reached in 1–2 hours. Food increases exposure, so Ibrutinib should be taken consistently with or without food.
• Distribution: Highly (~97%) bound to plasma proteins.
• Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 3A4 (CYP3A4), to an active metabolite (dihydrodiol-ibrutinib, less potent than the parent).
• Elimination: Predominantly excreted in feces, with minimal (<10%) renal excretion. Elimination half-life is approximately 4–13 hours.

Swallow Ibruxen capsules whole with water at about the same time every day; do not open, crush, dissolve, or chew them. Take consistently with or without food. Avoid grapefruit and Seville oranges. If vomiting occurs after a dose, do not take a replacement dose; resume the normal schedule at the next scheduled time.

CYP3A4 inhibitors

Ibruxen is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir) substantially increases Ibruxen plasma levels and toxicity risk; concurrent use should generally be avoided, or the Ibruxen dose reduced substantially with close monitoring if unavoidable. Moderate CYP3A4 inhibitors (e.g., fluconazole, diltiazem, erythromycin, ciprofloxacin) also raise Ibruxen levels and require a reduced Ibruxen dose.

CYP3A4 inducers

Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can markedly reduce Ibruxen plasma concentrations and efficacy; concurrent use should be avoided.

Grapefruit and Seville oranges

These inhibit intestinal CYP3A4 and can increase Ibruxen exposure; they should be avoided during treatment.

Antiplatelet agents and anticoagulants

Ibruxen increases the risk of bleeding (see Precautions and Warnings). Concurrent use of antiplatelet drugs (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin, direct oral anticoagulants) further raises hemorrhage risk; warfarin and other vitamin K antagonists should generally be avoided in favor of alternative anticoagulation where possible, with close monitoring if concurrent use is unavoidable.

The most common adverse effects of Ibruxen, several of which relate to its serious safety risks discussed under Precautions and Warnings, include:

• Diarrhea, nausea, constipation, mouth sores (stomatitis)
• Fatigue, musculoskeletal pain, arthralgia
• Bruising (contusion) and other minor bleeding/rash
• Low blood counts: thrombocytopenia, neutropenia, anemia
• Upper respiratory tract infections, fever
• Peripheral edema
• Hypertension

Less common but serious effects — major hemorrhage, severe infections, cardiac arrhythmias (including atrial fibrillation/flutter), secondary cancers, and tumor lysis syndrome — are covered under Precautions and Warnings, as these require specific monitoring and clinical action rather than routine tolerance.

Pregnancy: Based on findings in animal reproduction studies, Ibruxen can cause fetal harm and is generally strictly avoided during pregnancy. Ibruxen should be used in pregnancy only if clearly needed and if the potential benefit to the mother is judged to justify the potential risk to the fetus, and only under close physician supervision. Females of reproductive potential should use effective contraception during treatment and for at least one month after the last dose; male patients with partners of reproductive potential should also use effective contraception during and after treatment as advised by their physician.

Lactation: It is not known whether Ibruxen passes into human breast milk, but because of the potential for serious adverse effects in a nursing infant, breastfeeding is not advised during treatment and for at least one week after the final dose. Discuss infant feeding plans with your physician before starting Ibruxen.

Ibruxen carries several serious risks that require careful patient selection and monitoring throughout treatment:

• Hemorrhage: Serious and sometimes fatal bleeding events (including gastrointestinal, intracranial, and other major hemorrhage) have occurred. Risk is increased with concomitant antiplatelet or anticoagulant therapy. Ibruxen should be temporarily withheld for at least 3–7 days before and after surgical or invasive procedures, with the exact duration depending on the type of surgery and bleeding risk, as advised by the treating physician.
• Infections: Serious, including fatal, infections have occurred, including opportunistic infections such as Pneumocystis jirovecii pneumonia, invasive fungal infections, and reactivation of hepatitis B virus. Patients should be monitored for signs of infection and evaluated promptly if fever or infection signs develop; hepatitis B testing before starting therapy is advised.
• Cytopenias: Neutropenia, thrombocytopenia, and anemia (including Grade 3–4) are common; regular complete blood count monitoring is required.
• Cardiac arrhythmias: Atrial fibrillation and atrial flutter occur at increased frequency, and other serious ventricular arrhythmias (some fatal) have been reported, particularly in patients with cardiac risk factors, hypertension, or prior arrhythmia. Patients should be monitored clinically for symptoms of arrhythmia (palpitations, dizziness, syncope) with ECG evaluation as needed.
• Hypertension: New or worsening high blood pressure has occurred; blood pressure should be monitored and managed throughout treatment.
• Second primary malignancies: Other cancers, including skin cancers and other solid tumors, have developed in patients receiving Ibruxen; routine skin examination is recommended.
• Tumor lysis syndrome: Rare but can be serious, particularly in patients with high tumor burden before starting treatment; adequate hydration, monitoring of electrolytes/uric acid, and prophylaxis should be considered in at-risk patients.

Because of these risks, Ibruxen should only be prescribed and monitored by a physician experienced in treating hematologic malignancies, with regular clinical and laboratory follow-up.

There is limited clinical experience with Ibruxen overdose. In the event of a suspected overdose, patients should be monitored closely for signs of the known adverse effects described above (particularly bleeding, infection, and cardiac arrhythmia) and given appropriate supportive care. There is no specific antidote for Ibruxen. Anyone who has taken more than the prescribed dose, or a caregiver who suspects an overdose, should seek immediate medical attention or contact emergency services / a poison control center rather than attempting home management.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly patients: Patients aged 65 years and older may experience a higher rate of atrial fibrillation and Grade 3 or higher adverse events with Ibruxen; closer clinical monitoring is advised in this age group.
• Hepatic impairment: Dose reduction is required in mild-to-moderate impairment, and Ibruxen is generally avoided in severe hepatic impairment unless benefit clearly outweighs risk (see Dosage and Administration).
• Renal impairment: No adjustment generally needed for mild-to-moderate impairment; caution and close monitoring advised in severe renal impairment or dialysis, given limited data.
• Pediatric patients: Ibruxen is approved for chronic GVHD in children 1 year of age and older, using weight/body-surface-area-based dosing. Safety and efficacy for other indications (CLL/SLL, Waldenström's macroglobulinemia) have not been established in children and Ibruxen is not used for these indications in pediatric patients outside of clinical trials.

For CLL/SLL and Waldenström's macroglobulinemia, Ibruxen is typically continued long-term, until disease progression or until toxicity becomes unacceptable. For chronic GVHD, treatment continues based on clinical response, with the physician periodically reassessing whether ongoing therapy is warranted. Treatment duration should always be determined and reviewed by the prescribing hematologist/oncologist.

Ibrutinib is classified as an antineoplastic agent, targeted small-molecule kinase inhibitor, specifically a Bruton's tyrosine kinase (BTK) inhibitor.

Ibrutinib irreversibly binds to a cysteine residue in the active site of Bruton's tyrosine kinase (BTK), blocking BTK-mediated signaling downstream of the B-cell receptor. This interrupts the proliferation, survival, and migration signals malignant B-cells rely on, and (via additional inhibition of ITK) dampens pathogenic T-cell activity relevant to chronic graft-versus-host disease.

Ibruxen is approved for use in children 1 year of age and older for chronic graft-versus-host disease after failure of one or more lines of systemic therapy, dosed at 240 mg/m² body surface area once daily (maximum 420 mg/day) for those under 12 years, and 420 mg once daily for those 12 years and older. Safety and effectiveness of Ibruxen for other indications, such as CLL/SLL or Waldenström's macroglobulinemia, have not been established in the pediatric population, and Ibruxen should not be used for these indications in children outside a clinical trial setting.